Participant flow

Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) · Source last updated 2017-06-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Temozolomide capsules 150 mg/m\^2 daily on a 7-day on/7-day off schedule for each 28-day cycle. Temozolomide is the only treatment group, and and all participants received the same dosing regimen.

   id

   FG000

   title

   Temozolomide

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         11

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         69

      type

      Progression of disease being studied

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Non-compliance with protocol

   5. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Administrative

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         86

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         86

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice